Captor Therapeutics (CTX) Q3 2025 earnings summary

Executive summary

• Revenue from R&D services dropped to PLN 4.6m for the nine months ended September 30, 2025, from PLN 12.9m year-over-year, mainly due to lower collaboration income.

• Net loss widened to PLN 32.0m from PLN 29.7m year-over-year, reflecting higher R&D and administrative expenses.

• The company continued to incur operating losses, consistent with its early-stage biotech profile, and expects this trend to persist.

• Cash and cash equivalents decreased significantly to PLN 3.9m from PLN 39.3m at the start of the year.

Financial highlights

• Operating loss for the period was PLN 33.3m, compared to PLN 30.2m in the prior year.

• Grant revenue increased to PLN 5.1m from PLN 3.7m year-over-year.

• Total assets fell to PLN 44.5m from PLN 87.5m at year-end 2024.

• No dividends were paid or proposed.

Outlook and guidance

• Financial resources and expected grant proceeds are projected to fund operations until June 2026.

• The company is actively seeking additional financing, including new research collaborations and potential share issuance in early 2026.

• A grant agreement was signed in October under the EIC Accelerator program, providing both funding and validation of research quality.